Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia.

BACKGROUND: Antiepileptic drugs are the first-line treatment for trigeminal neuralgia (TN). Carbamazepine and oxcarbazepine are the most studied with well-known efficacy. Eslicarbazepine acetate is a third-generation antiepileptic drug that has not previously been evaluated for the treatment of TN. We aim to assess the efficacy, tolerability and safety of eslicarbazepine for TN. DESIGN AND METHODS: Retrospective, open-label, multicentric, intention-to-treat study. We included patients older than 18 years who met the ICHD-3 beta diagnostic criteria for TN. We evaluated the variation of intensity and frequency of pain paroxysms before and after treatment with eslicarbazepine. Secondary objectives assessed were tolerability and safety of eslicarbazepine. RESULTS: Eighteen patients were included, 15 women, mean age 65.2 years old, mean follow-up 21.1 months. The mean number of drugs tested before eslicarbazepine was 2; 10 patients used eslicarbazepine as monotherapy. After the treatment with ESL, the median of pain intensity improved from 9.5 to 2.5 (p < 0.001) and the median of pain paroxysms frequency improved from 70 episodes per week to 0.37 (p < 0.001). Responder rate was 88.9%; 44.4% became asymptomatic after treatment. Sixty-one per cent of patients presented some adverse event; four patients discontinued eslicarbazepine for this reason. Despite this, 16 patients (88.9%) noticed a good subjective tolerance to eslicarbazepine. The retention rate at 6 months was 77.8% and at 12 months 61.1%. CONCLUSIONS: Our study supports the hypothesis that eslicarbazepine acetate is an effective, safe and well-tolerated treatment for the treatment of TN. Further studies are warranted to corroborate these results. SIGNIFICANCE: Eslicarbazepine acetate has shown to be an effective, safe and well-tolerated drug for TN. This is the first study that evaluated the efficacy of this drug on TN in humans.

Drusas de la cabeza del nervio óptico / Optic nerve head drusen

No disponible

Fibrinólisis intravenosa en un varón de 14 años con infarto cerebral por disección de la arteria carótida interna / Intravenous fibrinolysis in a 14-year-old male with cerebral infarction due to dissection of the internal carotid artery

No disponible

Estimulación cerebral profunda en la enfermedad de Parkinson / Deep brain stimulation in Parkinson's disease

Introducción. Desde su aparición en la década de los noventa, la estimulación cerebral profunda se ha impuesto como una alternativa terapéutica segura y eficaz en la enfermedad de Parkinson, estando indicada cuando aparecen complicaciones motoras incontrolables con el tratamiento farmacológico. Objetivo. Realizar una revisión actualizada de la literatura médica sobre los aspectos más importantes de esta cirugía funcional. Desarrollo. Aunque su mecanismo de acción a día de hoy continúa siendo desconocido, se ha postulado que ejerce una acción inhibitoria sobre la actividad de los núcleos subtalámico y globo pálido interno, que se encuentra exaltada en enfermos parkinsonianos. La técnica quirúrgica de elección es la estimulación del núcleo subtalámico. Ha demostrado tener unos resultados favorables tanto desde el punto de vista motor, con una mejoría significativa de los síntomas cardinales de la enfermedad, como en la calidad de vida de estos pacientes. El éxito de la cirugía depende de tres pasos fundamentales: 1) La adecuada selección del candidato quirúrgico, teniendo en cuenta las recomendaciones de los principales grupos de estudio sobre factores pronóstico como son la edad, el tiempo de evolución y la presencia de síntomas resistentes a la levodopa. 2) La correcta posición del electrodo en la diana quirúrgica. 3) La programación del sistema de estimulación. Conclusión. La estimulación cerebral profunda del núcleo subtalámico es una opción terapéutica claramente establecida en la enfermedad de Parkinson avanzada, cuyo desarrollo en los últimos años, ha favorecido la obtención de unos resultados clínicos favorables cuando el tratamiento farmacológico fracasa (AU)

Introduction. Since its appearance in the nineties, deep brain stimulation has proved itself to be a safe, effective therapeutic alternative in Parkinson's disease, and is indicated when there are motor complications that pharmacological treatment fails to control. Aims. The purpose of this work is to conduct an updated review of the medical literature on the most important aspects of this functional surgery. Development. Although today its mechanism of action remains unknown, it has been suggested that it exerts an inhibitory action on the activity of the subthalamic nuclei and internal globus pallidus, which is found to be overexcited in patients with parkinsonism. The preferred surgical technique is subthalamic nucleus stimulation. This procedure has proved to yield favourable results both from the motor point of view, with a significant improvement in the cardinal symptoms of the disease, and as regards these patients’ quality of life. The success of the surgical procedure depends on three fundamental steps: 1) Selection of a suitable candidate for surgery, taking into account the recommendations of the main study groups on prognostic factors, such as age, time to progression and the presence of symptoms that are resistant to levodopa; 2) The correct position of the electrode on the surgical target; 3) The programming of the stimulation system. Conclusions. Deep brain stimulation of the subthalamic nucleus is a clearly established therapeutic option in advanced Parkinson's disease. Recent developments allow favourable clinical outcomes to be obtained when pharmacological treatment fails (AU)

Miscelánea: parkinsonismo en otras enfermedades degenerativas / Miscellany: Parkinsonism in other degenerative diseases

Introducción. El parkinsonismo en otras enfermedades neurodegenerativas es un tema amplio y variado. Describiremos las características diferenciadoras de algunas entidades bien definidas (enfermedad de Huntington, enfermedad de Wilson), así como de otras más raras. Desarrollo. Existen gran cantidad de trastornos neurodegenerativos que cursan con parkinsonismo en algún momento de su evolución. Es necesario reconocer marcadores clínicos diferenciadores (edad de inicio, corea, hepatopatía, parálisis supranuclear de la mirada, respuesta a levodopa...), así como patrones de herencia y de neuroimagen que nos permitan reconocer cuadros clínicos definidos. Conclusiones. Todo cuadro de parkinsonismo debe estudiarse cuidadosamente. Debemos identificar aquellos cuadros con especial importancia por su frecuencia (enfermedad de Huntington) o por ser potencialmente curables (enfermedad de Wilson), en especial en todos los pacientes con un inicio juvenil. Otras entidades infrecuentes (hemiatrofia-hemiparkinson, síndrome pálido-piramidal, enfermedades por depósito, neuroacantocitosis, etc), también deben ser consideradas en el diagnóstico diferencial (AU)

Introduction. Parkinsonism in other neurodegenerative diseases is a broad and varied topic. We report the differentiating features of some well-defined conditions (Huntington's disease, Wilson's disease), as well as some other rarer ones. Development. There are many neurodegenerative disorders that are accompanied by parkinsonism at some point in their development. It is necessary to recognise differentiating clinical markers (age at onset, chorea, liver disease, supranuclear gaze palsy, response to levodopa, and so on) as well as inheritance and neuroimaging patterns that enable us to recognise defined clinical pictures. Conclusions. very clinical picture suggestive of parkinsonism must be studied carefully. We must identify those clinical patterns that are especially important due to their frequency (Huntington's disease) or because they are potentially curable (Wilson's disease), particularly in all patients with onset prior to adulthood. Other infrequent conditions (hemiatrophyhemiparkinsonism, pallidal-pyramidal syndrome, diseases due to deposits, neuroacanthocytosis, etc.) should also be taken into account in the differential diagnosis (AU)